Founded in 2010 with the ambition to fight cancer, Ecrins Therapeutics is also committed to delivering value to its shareholders.
We strive to convert innovative science into efficient therapeutic products – promising a high return on investment.
Company profile
Incorporated – 2010
Ownership – private
Phase of development: clinical stage
Funding:
- Share capital €137 237.60
- More than €3 M of non-dilutive funding obtained
- €660K raised in 2015
- €680K raised in 2017
Management team:
- CEO and President: Andrei Popov, MD, PhD
- COO: Aurelie Juhem, PhD
Investment opportunity
Investing into Ecrins Therapeutics promises a high return on investment:
- In vivo validated drug candidate ET-D5 developed for the treatment of several aggressive forms of cancer in human and veterinary oncology
- Strong current IP and commitment to boost the IP portfolio
- Exit scheduled at the end of the Clinical Proof of Concept
For investor relations enquiries please contact us.
Our assets:
- ET-D5: first-in-class anti-cancer drug candidate with proven preclinical efficacy
- Worldwide exclusive license (WO2011107709A1 family of patents)
- Innovative and efficient drug discovery platform
- Seasoned team of managers and advisors with complementary scientific and industrial experiences
Partnerships
Ecrins Therapeutics is open to partnerships with pharmaceutical industry to implement its challenging R&D programs.